Graft Versus Host Disease (GVHD)

Highlights - Tomostrocel is a multi-donor bone marrow-derived MSC product in late-stage development - Real-world data of 317 adult aGvHD patients treated with tomostrocel are analyzed - 75% of patients had prior ruxolitinib, >90% had grade III/IV and/or lower GI-aGvHD - The Day…

Highlights Reduced cumulative post-transplant cyclophosphamide (<100 mg/kg) was associated with increased acute GVHD. Lower PTCy exposure independently increased moderate-to-severe chronic GVHD and second-line GVHD treatment. Reduced PTCy exposure did not significantly affect…

Key Points Posttransplant cyclophosphamide significantly reduced GVHD incidence but not TA-TMA incidence, which predated acute GVHD in ∼50% of cases. TA-TMA biomarker soluble C5b-9 was not significant in adults; pre-HCT serum creatinine, placental growth factor, and day +28 ST2…

ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational…

Introduction Payers employ health care utilization–management strategies, including prior authorization (PA), to limit costs and promote evidence-based, guideline-concordant care. However, PA may be inconsistently applied and associated with patient confusion and frustration.1-3…

Highlights •There are no differences in NRM in patients receiving prior CAR T versus no CAR T. •There are no differences in GVHD in patients receiving prior CAR T versus no CAR T. •HCT within 3 months of CAR T had less grades III to IV acute GVHD. ABSTRACT It remains unclear…